Glucuronidation and chemical disposition
Anti-Doping Agency (USADA) has specifically identified BPC-157 as a prohibited experimental peptide for athletes, emphasizing the lack of FDA-approved indications and limited safety data
Being able to speak to it knowledgeably, including its limitations, is part of practicing responsibly in anti-aging and regenerative medicine
What may improve includes: Pain intensity and frequency Radiating symptoms (sciatica) Morning stiffness and mobility Tolerance for sitting, standing, and daily activities Sleep quality affected by pain Dependence on pain medications Many users with disc herniations report 50% to 80% improvement in symptoms while their imaging findings remain unchanged
Some compound is always active, some pathway is always engaged, and the repair process never fully stalls between administrations
Currently, multiple phase 3 trials with oral semaglutide and orforglipron are ongoing for different populations (NCT05803421), while another oral GLP-1 RA (CT-996) is in early phase clinical trials (Table 1)